Miguel Perales MD
@drmiguelperales.bsky.social
1.2K followers 600 following 250 posts
Chief Adult BMT MSKCC | Past-President ASTCT | Past Board Member NMDP | Chair Committee Transplant/Cell Ther ALLIANCE | Immigrant 🇪🇸🇬🇧 #MedSky Opinions mine/not MSK https://www.mskcc.org/cancer-care/doctors/miguel-angel-perales
Posts Media Videos Starter Packs
drmiguelperales.bsky.social
Very honored to give Ciril Rozmán Lecture at the annual meeting of the Spanish Society of Hematology and Hemotherapy @sehhematologia.bsky.social. The Ciril Rozmán Award recognizes a foreign hematologist who has made high-level scientific contributions and has had close ties with Spanish experts.
Reposted by Miguel Perales MD
hematorules.bsky.social
@drmiguelperales.bsky.social at #Hemato2025

VII Conferencia Ciril Rozman
Reposted by Miguel Perales MD
amartinezrocamd.bsky.social
Un merecido reconocimiento al @drmiguelperales.bsky.social por su larga trayectoria.

Siempre dispuesto a compartir conocimientos y procurar que los residentes de España puedan visitar @mskcancercenter.bsky.social. Para mi una de las mejores experiencias de mi residencia.
👏Muchas felicidades👏
Reposted by Miguel Perales MD
hemasphere-journal.bsky.social
🎙️New Podcast Episode!

Join host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities & the need for a structured grading system. 👉https://bit.ly/46xKjZA
drmiguelperales.bsky.social
Great session on cGVHD at #COSTEM2025 in Berlin last week. Got to debate Dr. Francesca Kinsella
drmiguelperales.bsky.social
Go see Art on Broadway. Great show!
Reposted by Miguel Perales MD
bmtinfonet.bsky.social
BMT InfoNet invites your patients to a free live webinar with leading CAR T-cell therapy experts.

Encourage your patients and caregivers to register and submit their questions in advance!

🗓 Tuesday, October 21
🕖 7:00 PM ET
🔗 bmtinfonet.org/event/ask-ca...
Reposted by Miguel Perales MD
gavinyamey.bsky.social
💉New study of HPV vaccine shows “robust population-level effectiveness & herd protection in adolescent girls & young women”

From 2006-2023:
➡️ Proportion of vaxxed women positive for high-risk HPV-16 & -18 types fell 98.4%, proportion of unvaxxed women fell 71.6%
1/2
jamanetwork.com/journals/jam...
Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine
This cross-sectional study investigates population-level effectiveness and herd protection in the first 17 years after human papillomavirus (HPV) vaccination among adolescent girls and young women at ...
jamanetwork.com
Reposted by Miguel Perales MD
nejm.org
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. Read the full report: nej.md/48gcBZV

#MedSky #GastroSky
A graph showing the circulating B-cell counts before and after treatment with blinatumomab and with chimeric antigen receptor (CAR) T cells targeting CD19.
Reposted by Miguel Perales MD
bachynski.bsky.social
This is huge: “A drug that provides near-perfect protection against H.I.V. with shots just twice a year will be made available at $40 per patient annually in low- and middle-income countries, offering new hope… making lenacapavir a realistic choice in countries with constrained resources.”
Philanthropies Strike a Promising Deal to Turn Back H.I.V.
www.nytimes.com
Reposted by Miguel Perales MD
aspho-hq.bsky.social
Today is World Marrow Donor Day! We hope you will join us today in thanking the selfless individuals who register and donate stem cells to save the lives of patients in need. #WMDD25 #PedsHemeOnc #PHODocs #hematology
Reposted by Miguel Perales MD
mskcancercenter.bsky.social
MSK pediatric hematologist-oncologist Dr. Neerav Shukla, who led the research, shares that the testing provides real-time diagnostic, prognostic, and therapeutic information to local physicians and their patients. Learn more ⬇️
MSK Research Highlights, September 4, 2025
New MSK research shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental antibody that shows promise against metastatic ...
www.mskcc.org
Reposted by Miguel Perales MD
mskdeptofmed.bsky.social
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.

🗓️ Thursday, September 18 | 4:40 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
Reposted by Miguel Perales MD
mskdeptofmed.bsky.social
At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm

🗓️ Saturday, September 20 | 9:20 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
Reposted by Miguel Perales MD
drtomfrieden.bsky.social
The announcement of health insurance companies that they’ll continue covering routine vaccinations is a huge vote of no confidence in ACIP's recommendations. It reflects a desire by insurers to avoid the cost of illnesses by having their customers vaccinated.

Gift link:
Questions Are Raised About Vaccine Panel’s Reliability as Policy Review Gets Underway
www.nytimes.com
Reposted by Miguel Perales MD
mskdeptofmed.bsky.social
Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm

🗓️ Friday, September 19 | 9:40 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social
Reposted by Miguel Perales MD
ascocancer.bsky.social
There are 18 million cancer survivors in the U.S. That’s 6x more than there were 50 years ago, thanks to decades of progress driven in large part by federally funded research. We can’t go back.

Take action with us: brnw.ch/21wVV2D
#SaveResearchStopCancer #ASCOAdvocacy
Reposted by Miguel Perales MD
jco-asco.bsky.social
We're thrilled to be here on BlueSky to bring you the latest practice-changing oncology research from all six JCO Journals! Follow-us for great content from #JCO, #JCOOP, #JCOGO, #JCOPO, #JCOCCI, & #JCOOA.